Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments ...

Biogen said on Monday insider Robin Kramer will take over as the drugmaker's finance chief after incumbent Michael McDonnell ...

Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA ...

Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare ...